Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME

Abstract Aims The EMPA‐REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium–glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease over a study period of 3 years. We aimed to inves...

Full description

Bibliographic Details
Main Authors: Pierpaolo Pellicori, Anne Pernille Ofstad, David Fitchett, Cordula Zeller, Christoph Wanner, Jyothis George, Bernard Zinman, Martina Brueckmann, JoAnn Lindenfeld
Format: Article
Language:English
Published: Wiley 2020-12-01
Series:ESC Heart Failure
Subjects:
Empagliflozin
EMPA‐REG OUTCOME
Trial
Heart failure
Diabetes
Online Access:https://doi.org/10.1002/ehf2.12891

Internet

https://doi.org/10.1002/ehf2.12891

Similar Items